BioCentury | May 23, 2011
Financial News

VistaGen completes venture financing

...Fund; accredited investors Note: VistGen completed the offering prior to its reverse-merger with shell company Excaliber Enterprises Ltd....
BioCentury | May 23, 2011
Company News

VistaGen, Excalib deal

...pain. AV-101 is an NMDA receptor antagonist. VistaGen Therapeutics Inc. , South San Francisco, Calif. Excaliber Enterprises Ltd....
Items per page:
1 - 2 of 2
BioCentury | May 23, 2011
Financial News

VistaGen completes venture financing

...Fund; accredited investors Note: VistGen completed the offering prior to its reverse-merger with shell company Excaliber Enterprises Ltd....
BioCentury | May 23, 2011
Company News

VistaGen, Excalib deal

...pain. AV-101 is an NMDA receptor antagonist. VistaGen Therapeutics Inc. , South San Francisco, Calif. Excaliber Enterprises Ltd....
Items per page:
1 - 2 of 2